SABSSAB Biotherapeutics Inc

Why Is H.C. Wainwright Bullish On SAB Biotherapeutics (SABS) With $10 Price Target...

Barclays Assigns Overweight Rating to SAB Biotherapeutics Inc. (SABS...

Biotechnology and healthcare innovation dominated investor conversations today as multiple companies delivered meaningful corporate, clinical, regulatory, and commercialization updates. From artificial intelligence-powered drug discovery platforms to neuro-oncology, regenerative medicine, wound care technologies, and autoimmune disease therapies, investors focused on companies that could potentially benefit from major industry trends while advancing important milestones of their own. $CUPR, $HYFT, $NTHI, $RGNT, $GELS, $SABS

The HHS confirmed that one American passenger evacuated from the MV Hondius cruise ship tested mildly positive for the Andes strain of hantavirus.

SAB Biotherapeutics, Inc. (NASDAQ:SABS - Get Free Report) has been assigned an average rating of "Moderate Buy" from the eight ratings firms that are presently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, five have assigned a buy reco...

SAB Biotherapeutics (NASDAQ:SABS) will be releasing its Q1 2026 earnings before the market opens on Friday, May 8. (View Earnings Report at...

SAB Biotherapeutics, Inc. (NASDAQ:SABS - Get Free Report) saw a large increase in short interest in April. As of April 15th, there was short interest totaling 3,000,764 shares, an increase of 19.8...

Shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS - Get Free Report) have earned a consensus rating of "Moderate Buy" from the eight analysts that are covering the firm, Marketbeat Ratings reports...

Rodman & Renshaw initiated coverage on SAB Biotherapeutics in a report on Thursday. They issued a "buy" rating and a $13.00 target price on the stock...